The Enterprise Value as of September 2024 (TTM) for FibroGen, Inc. (FGEN) is 62.22M

According to FibroGen, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 62.22M. This represents a change of -62.17% compared to the average of 164.48M of the last 4 quarters.

FibroGen, Inc. (FGEN) Historical Enterprise Value (quarterly & annually)

How has FGEN Enterprise Value performed in the past?

The mean historical Enterprise Value of FibroGen, Inc. over the last ten years is 1.94B. The current 62.22M Enterprise Value has changed 220.50% with respect to the historical average. Over the past ten years (40 quarters), FGEN's Enterprise Value was at its highest in in the March 2019 quarter at 4.74B. The Enterprise Value was at its lowest in in the June 2024 quarter at 99.95M.

FibroGen, Inc. (FGEN) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of FibroGen, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

FibroGen, Inc. (FGEN) Average Enterprise Value

How has FGEN Enterprise Value performed in the past?

The current Enterprise Value of FibroGen, Inc. (FGEN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

FibroGen, Inc. (FGEN) Enterprise Value vs. Peers

How is FGEN’s Enterprise Value compared to its peers?

FibroGen, Inc.’s Enterprise Value is less than Ardelyx, Inc. (1.38B), greater than Zura Bio Limited (42.42M), greater than Hepion Pharmaceuticals, Inc. (2.24M), greater than AVROBIO, Inc. (-85302404.00), greater than Verastem, Inc. (55.08M), less than Mereo BioPharma Group plc (582.99M), less than Blueprint Medicines Corporation (6.16B), less than Agios Pharmaceuticals, Inc. (2.44B), less than Day One Biopharmaceuticals, Inc. (1.01B), less than BioMarin Pharmaceutical Inc. (16.13B), less than Lyell Immunopharma, Inc. (226.32M), less than Cullinan Oncology, Inc. (930.13M), less than Monte Rosa Therapeutics, Inc. (284.72M), less than Theseus Pharmaceuticals, Inc. (138.26M), less than Revolution Medicines, Inc. (6.80B), less than Biomea Fusion, Inc. (153.42M), less than Stoke Therapeutics, Inc. (586.20M), less than Akero Therapeutics, Inc. (1.56B), greater than Homology Medicines, Inc. (-103303255.00), less than Gossamer Bio, Inc. (317.87M), less than Vaxcyte, Inc. (11.96B), less than Larimar Therapeutics, Inc. (486.93M), less than Syndax Pharmaceuticals, Inc. (1.52B), less than Merus N.V. (2.79B), less than Sutro Biopharma, Inc. (437.33M),

Build a custom stock screener for FibroGen, Inc. (FGEN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like FibroGen, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

FibroGen, Inc. (FGEN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like FibroGen, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.